ClinicalTrials.gg
CompletedNCT01286558Updated Jun 27, 2014Results posted

Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)

A Phase 3 interventional study of 40 mg telmisartan and 5 mg amlodipine in Hypertension, sponsored by Boehringer Ingelheim. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
47th of 99
225 · median 184
Started
2011
the only one that year
Phase 3
40 of 99
none open now
Registered
44th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 47th largest by enrollment, is the only one that started in 2011, is one of 40 in phase 3, and was the 44th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

Blood pressure in hypertensive patients is rarely controlled to an optimal level by one drug alone, often a combination of two or more drugs is essential to achieve a sufficient antihypertensive effect. Therefore in Japanese Society of Hypertension (JSH) 2009 combination therapy is recommended. In JSH 2009 it is advised to start the combination therapy at a low dose, and to increase the dosage when the antihypertensive effect is not sufficient. In the Japanese long-term safety study, 259 patients received the T40/A5 mg fixed-dose combination (FDC), and after 6 weeks treatment 48 patients of them could not control their blood pressure (DBP =90) (U09-2494-01). For those patients who cannot control their blood pressure with T40/A5 mg FDC, a switch to a higher dose such as T80/A5 mg is recommended.

In the overseas 4x4 factorial design trial, a clinically meaningful difference of the blood pressure lowering effect between T80/A5 mg free combination and T40/A5 mg free combination was shown (U07-3503-02). But the sponsor has no data that verifies this difference in Japanese patients.

Thus, this clinical trial is being conducted to investigate the antihypertensive effect and safety of high dose T80/A5 mg FDC compared with low dose T40/A5 mg FDC in Japanese patients with essential hypertension. In this trial, a multi-centre, randomised, double-blind, double-dummy, active-controlled, parallel group comparison method is employed.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Essential hypertensive patients

    • If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be >=90 and >=114 mmHg
    • If not taking any antihypertensive drugs, mean seated DBP must be >=95 and >=114 mmHg
  2. Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.

Exclusion criteria

Exclusion criteria:

  1. Patients taking 3 or more antihypertensive drugs at signing the form
  2. Patients with known or suspected secondary hypertension
  3. Patients with cardiac arrhythmia
  4. Congestive heart failure with (NYHA) functional class III-IV
  5. Patients with recent cardiovascular events
  6. Patients with a history of stroke or within last 6 months before signing the informed consent form
  7. Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy
  8. Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors
  9. Patients with known to any component of the product, or a known hypersensitivity to dihydropyridine-derived drugs
  10. Patients with hepatic and/or renal dysfunction
  11. Pre-menopausal women who are nursing or pregnant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
225 participants (actual)

Study arms

  • Experimental
    80mg telmisartan and 5mg amlodipine FDC

    once daily

    Drug: 5 mg amlodipine · Drug: 80 mg telmisartan

  • Active comparator
    40mg telmisartan and 5mg amlodipine FDC

    once daily

    Drug: 40 mg telmisartan · Drug: 5 mg amlodipine

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough

    Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing

    Time frame: Reference baseline, 8 weeks

Secondary outcomes

  1. Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough

    Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing

    Time frame: Reference baseline, 8 weeks

  2. Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP

    Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined

    Time frame: Reference baseline, 8 weeks

  3. Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP

    Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined

    Time frame: Reference baseline, 8 weeks

  4. Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP

    Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined

    Time frame: Pseudo-baseline, 14 weeks

  5. Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP

    Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined

    Time frame: Pseudo-baseline, 14 weeks

  6. Changes From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM

    Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined

    Time frame: Reference baseline, 8 weeks

  7. Changes From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM

    Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined

    Time frame: Reference baseline, 8 weeks

  8. Seated DBP Control Rate at Trough

    DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

  9. Seated SBP Control Rate at Trough

    SBP control rate: The rate of patients with controlled seated DBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

  10. Seated DBP Response Rate at Trough

    DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (\<90 mmHg and/or reduction from reference baseline \>=10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

  11. Seated SBP Response Rate at Trough

    SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (\<140 mmHg and/or reduction from reference baseline \>=20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

  12. Seated Blood Pressure (BP) Normalisation at Trough

    Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

07

Results

Posted Oct 22, 2012

Participant flow

Participant flow — Overall Study
Milestone80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Started112113
Completed111111
Not completed12
Withdrew: Adverse event11
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryReduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough

Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing

Time frame:
Reference baseline, 8 weeks
Reported as:
Least squares mean · mm Hg
Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough
mm Hg80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough4.93 ± 0.613.47 ± 0.61
Statistical analysis
  • 80 mg Telmisartan and 5 mg Amlodipine FDC vs 40 mg Telmisartan and 5 mg Amlodipine FDC · ANCOVA · Mean difference (final values): 1.46 · 95% CI -0.22 to 3.14
SecondaryReduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough

Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing

Time frame:
Reference baseline, 8 weeks
Reported as:
Least squares mean · mm Hg
Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough
mm Hg80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough5.55 ± 0.903.41 ± 0.91
Statistical analysis
  • 80 mg Telmisartan and 5 mg Amlodipine FDC vs 40 mg Telmisartan and 5 mg Amlodipine FDC · ANCOVA · Mean difference (final values): 2.14 · 95% CI -0.36 to 4.64
SecondaryChanges From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP

Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined

Time frame:
Reference baseline, 8 weeks
Reported as:
Least squares mean · mm Hg
Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP
mm Hg80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP-1.54 ± 0.49-0.33 ± 0.49
Statistical analysis
  • 80 mg Telmisartan and 5 mg Amlodipine FDC vs 40 mg Telmisartan and 5 mg Amlodipine FDC · ANCOVA · Mean difference (final values): -1.21 · 95% CI -2.58 to 0.15
SecondaryChanges From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP

Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined

Time frame:
Reference baseline, 8 weeks
Reported as:
Least squares mean · mm Hg
Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
mm Hg80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP-2.81 ± 0.81-0.91 ± 0.82
Statistical analysis
  • 80 mg Telmisartan and 5 mg Amlodipine FDC vs 40 mg Telmisartan and 5 mg Amlodipine FDC · ANCOVA · Mean difference (final values): -1.90 · 95% CI -4.16 to 0.35
SecondaryChanges From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP

Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined

Time frame:
Pseudo-baseline, 14 weeks
Reported as:
Least squares mean · mm Hg
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP
mm Hg80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP-12.16 ± 0.61-11.28 ± 0.60
Statistical analysis
  • 80 mg Telmisartan and 5 mg Amlodipine FDC vs 40 mg Telmisartan and 5 mg Amlodipine FDC · ANCOVA · Mean difference (final values): -0.89 · 95% CI -2.57 to 0.79
SecondaryChanges From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP

Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined

Time frame:
Pseudo-baseline, 14 weeks
Reported as:
Least squares mean · mm Hg
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
mm Hg80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP-20.96 ± 0.96-19.32 ± 0.95
Statistical analysis
  • 80 mg Telmisartan and 5 mg Amlodipine FDC vs 40 mg Telmisartan and 5 mg Amlodipine FDC · ANCOVA · Mean difference (final values): -1.64 · 95% CI -4.27 to 0.99
SecondaryChanges From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM

Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined

Time frame:
Reference baseline, 8 weeks
Reported as:
Mean · mm Hg
Changes From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
mm Hg80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Hour 1-1.04 ± 10.27-0.22 ± 12.38
Hour 2-1.95 ± 11.440.32 ± 10.93
Hour 3-2.25 ± 11.862.87 ± 11.61
Hour 4-3.69 ± 12.43-0.02 ± 10.63
Hour 5-1.39 ± 13.22-0.75 ± 14.06
Hour 6-1.58 ± 11.08-0.86 ± 13.32
Hour 7-0.40 ± 12.24-1.25 ± 13.22
Hour 8-1.58 ± 13.230.55 ± 13.83
Hour 9-2.77 ± 12.83-0.73 ± 12.44
Hour 10-2.80 ± 13.75-0.14 ± 11.58
Hour 11-1.47 ± 11.58-1.16 ± 12.05
Hour 12-0.74 ± 11.86-1.43 ± 13.65
Hour 13-2.33 ± 12.96-1.05 ± 12.03
Hour 14-0.53 ± 15.49-0.08 ± 11.36
Hour 15-0.36 ± 13.651.86 ± 10.88
Hour 16-0.01 ± 10.730.85 ± 10.97
Hour 170.70 ± 12.16-0.80 ± 11.07
Hour 18-1.89 ± 11.811.02 ± 10.33
Hour 19-3.12 ± 12.960.10 ± 10.38
Hour 200.23 ± 11.03-1.27 ± 11.93
Hour 21-3.25 ± 12.85-0.90 ± 10.81
Hour 22-2.00 ± 11.83-1.67 ± 13.14
Hour 23-2.07 ± 12.05-0.53 ± 11.95
Hour 24-0.82 ± 9.370.42 ± 11.23
SecondaryChanges From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM

Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined

Time frame:
Reference baseline, 8 weeks
Reported as:
Mean · mm Hg
Changes From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
mm Hg80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Hour 1-6.54 ± 16.03-1.78 ± 16.37
Hour 2-2.78 ± 14.98-0.28 ± 15.82
Hour 3-3.41 ± 16.832.72 ± 17.74
Hour 4-4.72 ± 18.42-1.88 ± 17.03
Hour 5-1.14 ± 18.23-2.54 ± 20.71
Hour 6-1.68 ± 18.39-2.48 ± 20.01
Hour 7-0.60 ± 19.12-2.45 ± 18.69
Hour 8-2.05 ± 20.40-0.27 ± 22.07
Hour 9-3.09 ± 17.35-1.17 ± 18.33
Hour 10-5.78 ± 19.61-0.70 ± 18.91
Hour 11-2.04 ± 19.590.69 ± 15.16
Hour 12-4.57 ± 17.540.61 ± 16.89
Hour 13-2.27 ± 19.900.26 ± 17.53
Hour 14-1.46 ± 21.12-1.09 ± 17.49
Hour 15-1.21 ± 17.861.41 ± 17.70
Hour 16-0.78 ± 17.180.68 ± 15.42
Hour 17-0.71 ± 17.58-1.16 ± 15.67
Hour 18-2.66 ± 18.901.01 ± 15.84
Hour 19-4.58 ± 18.92-1.24 ± 15.30
Hour 200.57 ± 19.07-3.56 ± 17.02
Hour 21-4.02 ± 17.27-1.20 ± 16.47
Hour 22-3.88 ± 16.81-4.12 ± 17.40
Hour 23-4.65 ± 21.01-2.71 ± 16.15
Hour 24-2.24 ± 16.510.29 ± 16.09
SecondarySeated DBP Control Rate at Trough

DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Seated DBP Control Rate at Trough
percentage of participants80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
No53.160.0
Yes46.940.0
SecondarySeated SBP Control Rate at Trough

SBP control rate: The rate of patients with controlled seated DBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Seated SBP Control Rate at Trough
percentage of participants80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
No55.255.3
Yes44.844.7
SecondarySeated DBP Response Rate at Trough

DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (\<90 mmHg and/or reduction from reference baseline \>=10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Seated DBP Response Rate at Trough
percentage of participants80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
No29.532.1
Yes70.567.9
SecondarySeated SBP Response Rate at Trough

SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (\<140 mmHg and/or reduction from reference baseline \>=20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Seated SBP Response Rate at Trough
percentage of participants80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
No19.617.9
Yes80.482.1
SecondarySeated Blood Pressure (BP) Normalisation at Trough

Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · participants
Seated Blood Pressure (BP) Normalisation at Trough
participants80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
No4144
Optimal2113
Normal2326
High-normal2729

Adverse events

Collected over From first drug administration in the double-blind treatment period until 24 hours after the last dose, up to 69 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
80 mg Telmisartan and 5 mg Amlodipine FDC—1/112 (0.9%)6/112 (5.4%)
40 mg Telmisartan and 5 mg Amlodipine FDC—1/113 (0.9%)6/113 (5.3%)
Most frequent serious events
Most frequent serious events
Event80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
Cerebral artery occlusionNervous system disorders1/1120/113
Clavicle fractureInjury, poisoning and procedural complications0/1121/113
Most frequent other events
Most frequent other events
Event80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDC
NasopharyngitisInfections and infestations6/1126/113

Baseline characteristics

Age, Continuous
Age, Continuous(year)80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDCTotal
Mean54.6 ± 8.452.8 ± 9.453.7 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)80 mg Telmisartan and 5 mg Amlodipine FDC40 mg Telmisartan and 5 mg Amlodipine FDCTotal
Female232447
Male8989178
08

Study locations

8 sites
  • 1235.37.01 Boehringer Ingelheim Investigational Site
    Chuo-ku,Tokyo, Japan
  • 1235.37.07 Boehringer Ingelheim Investigational Site
    Hiroshima, Hiroshima, Japan
  • 1235.37.08 Boehringer Ingelheim Investigational Site
    Itoshima, Fukuoka, Japan
  • 1235.37.02 Boehringer Ingelheim Investigational Site
    Katsushika-ku, Tokyo, Japan
  • 1235.37.05 Boehringer Ingelheim Investigational Site
    Osaka, Osaka, Japan
  • 1235.37.03 Boehringer Ingelheim Investigational Site
    Ota-ku, Tokyo, Japan
  • 1235.37.06 Boehringer Ingelheim Investigational Site
    Suita, Osaka, Japan
  • 1235.37.04 Boehringer Ingelheim Investigational Site
    Yokohama, Kanagawa, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011 and a primary completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2011
First posted
Jan 31, 2011
Start
Jan 2011
Primary completionActual
Sep 2011
Results first posted
Oct 22, 2012
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01286558
Responsible party
Sponsor
First posted
Jan 31, 2011
Start date
Jan 2011
Primary completion
Sep 2011
Results posted
Oct 22, 2012
Last update
Jun 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion